- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SRPT
Recent news which mentions SRPT
Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript
February 28, 2023
Tickers
SRPT
From Motley Fool
FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments
February 28, 2023
From MarketWatch
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 28, 2023
From Benzinga
Earnings Scheduled For February 28, 2023
February 28, 2023
From Benzinga
3 Gene Editing Stocks With the Best Long-Term Potential
January 25, 2023
From InvestorPlace
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
Tags
NYSE:ABBV,NYSE:DIS,NYSE:PFE,NASDAQ:INCY,NASDAQ:EXEL,NASDAQ:CRSP,NASDAQ:VRTX,NASDAQ:SRPT,NASDAQ:CVAC
DIS
Stocks to Buy
From InvestorPlace
2 Under-the-Radar Biotech Stocks to Buy in 2023
January 06, 2023
From Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
December 09, 2022
From Motley Fool
Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript
November 03, 2022
Tickers
SRPT
From Motley Fool
Earnings Scheduled For November 2, 2022
November 02, 2022
From Benzinga
3 Unstoppable Stocks That Could Double in 5 Years
October 29, 2022
From Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2022
October 19, 2022
From Motley Fool
From Benzinga
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
September 28, 2022
From Benzinga
$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying
September 16, 2022
From Benzinga
A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
September 08, 2022
Tickers
SRPT
From Benzinga
FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial
September 06, 2022
Tickers
SRPT
From Benzinga
3 Biotech Stocks You Can Buy and Hold for the Next Decade
August 29, 2022
From Motley Fool
Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications
August 08, 2022
Tickers
SRPT
From Benzinga
Sarepta Therapeutics (SRPT) Q2 2022 Earnings Call Transcript
August 02, 2022
Tickers
SRPT
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.